Skip to main content
. 2018 Nov 21;38(47):10168–10179. doi: 10.1523/JNEUROSCI.3411-17.2018

Figure 9.

Figure 9.

Schematic illustration of the mechanisms for IL-2/IL-2Ab-afforded protection to the ischemic brain. IL-2/IL-2Ab treatment protects against ischemic brain injury by selectively expanding the number of Tregs in vivo and boosts the immunomodulatory function of Tregs. Elevated expression of CD39/CD73 on Tregs is important for IL-2/IL-2Ab-afforded neuroprotection. Detailed information about statistical analysis for each experiment is summarized in Table 9-1.